On December 4, 2023, the website of the Guangdong Provincial Department of Science and Technology released an announcement on the 3,300 Natural Science Fund general projects of the Guangdong Provincial Basic and Applied Basic Research Fund in 2024 (150,000/project) and 300 youth improvement projects (300,000/project). The publicity period is from December 4 to 10, 2023. Dr. Liao Yan, project leader of the Empowered Stem Cell Platform of the R&D Center of Shenzhen Beike Biotechnology Co., Ltd., once again won a Guangdong Basic and Applied Basic Research Fund Project (Youth Promotion).
This project mainly studies the therapeutic effect and key immune regulation mechanism of IL-18 empowered mesenchymal stem cells (IL-18-MSCs) on systemic lupus erythematosus (SLE). The in-depth research of this project aims to clarify the key mode of action of IL-18-MSCs in the treatment of autoimmune diseases such as SLE, and provide important theoretical and experimental basis for clinical translation. The new technology for empowering MSCs preparation developed by the project has improved the technical barriers in the stem cell industry and enhanced the market competitiveness of enterprises, andBeike Biotech has complete intellectual property protection and is one of its new product pipelines in the field of precision therapy in the future.
Beike Biotechnology R&D Center’s “Empowering Stem Cell Technology Platform” has achieved good scientific research output since its operation under the leadership of the professional technical team led by Dr. Liao Yan, the person in charge. In addition to receiving the Guangdong Basic and Applied Basic Research Fund Project (Youth Promotion) this time, Dr. Liao Yan has already won a project in 2020Guangdong Provincial Natural Science Foundation (General Project).
The source of the development of the biotechnology industry is innovative research and development. Sustained high investment in R&D is the core theme of biotechnology companies and the fundamental guarantee of continued vitality. It is also one of the important indicators to measure the R&D innovation strength and R&D innovation potential of enterprises. Beike Biotechnology has always been driven by systematic innovative research and development in the cutting-edge fields of life science and biotechnology. Since its establishment 18 years ago, the company has always adhered to independent research and development. It has formed Anktiva⢠cancer treatment platform, organoid research and development platform, human pluripotent stem cell research and development platform, empowered mesenchymal stem cell technology platform, biomaterials research and development platform, metabolomics research and development platform, exosome large-scale production and isolation and purification technology platformSeven major R&D platforms and seven ongoing scientific research projects,At the same time, Beike Biotechnology has applied for relevant patents in the biomedical fieldå©132 items, of which 106 items are authorized; undertake scientific research projects at national, provincial and municipal levels60remaining items; published papers related to the field of cells100+ 0px; outline: 0px; max-width: 100%; letter-spacing: 0.5px; box-sizing: border-box !important; overflow-wrap: break-word !important;”>, including SCI papers40+ articles, the cumulative impact factor (IF) of the paper reaches 200+. Especially in 2022, Beike Biotech was officially approved to establish an academician workstation, which opened up new channels for Beike Biotech to further enhance its research and development capabilities and enhance the core strength of the company.
At present, a new round of scientific and technological revolution and industrial transformation in the world is gaining momentum. The rapid development and widespread application of emerging technologies such as gene editing, biotherapy technology, big data, and artificial intelligence have pushed life sciences into a period of rapid development. In the future, Beike Biotech will continue to uphold its original intention of continuously promoting the transformation of scientific and technological achievements, continue to tackle technical problems, overcome “stuck neck” problems, promote iterative upgrades of technology in the cell field, and continue to move towards becoming an enterprise with core competitiveness in the field of stem cells.
News source: Guangdong Provincial Department of Science and Technology
